SCHEMBL5142353

SCHEMBL5142353

O=C(Nc1cccc(C(F)(F)F)c1)C(=Cc1cc(Cl)ccc1Cl)C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.54
P2RX1 P51575 1/20 0.54
P2RX4 Q99571 1/20 0.54
P2RX7 Q99572 1/20 0.54
TMPRSS4 Q9NRS4 1/20 0.54
NTRK1 P04629 1/20 0.53
CDK19 Q9BWU1 1/20 0.53
MAPT P10636 8/20 0.51
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
ALDH1A1 P00352 6/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C19 P33261 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HTT P42858 3/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5142354 0.91 MEN1 (0.54) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5145916 0.84 KDR (0.54) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5142680 0.84 MAPT (0.54) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5142706 0.83 MAPT (0.56) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5142747 0.83 KDR (0.57) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5142685 0.82 KDR (0.49) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5142369 0.82 MAPT (0.56) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5142735 0.81 MAPT (0.51) SLC2A1P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL5142676 0.81 CCR2 (0.52) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5145757 0.81 MEN1 (0.56) SLC2A1P2RX1P2RX4P2RX7TMPRSS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US claimed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO claimed
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US disclosed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CASP14, CASP2, CASP3 SLC2A1 4070/4885P2RX1 3776/4885P2RX4 4098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.